1 |
龚乙洪,覃 润,陈 璐,等. 前蛋白转化酶枯草溶菌素9抑制剂在冠心病中的研究进展[J]. 中国医药,2023, 18(5): 778-781.
|
2 |
Cammisotto V, Baratta F, Simeone PG, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) beyond lipids: The role in oxidative stress and thrombosis[J]. Antioxidants, 2022, 11(3): 569.
|
3 |
Grewal T, Buechler C. Emerging insights on the diverse roles of proprotein convertase subtilisin/kexin type 9 (PCSK9) in chronic liver diseases: Cholesterol metabolism and beyond[J]. Int J Mol Sci, 2022, 23(3): 1070.
|
4 |
Seidah NG, Garçon D. Expanding biology of PCSK9: Roles in atherosclerosis and beyond[J]. Curr Atheroscler Rep, 2022, 24(10): 821-830.
|
5 |
Katsuki S, K Jha P, Lupieri A, et al. Proprotein convertase subtilisin/Kexin 9 (PCSK9) promotes macrophage activation via LDL receptor-independent mechanisms[J]. Circ Res, 2022, 131(11): 873-889.
|
6 |
Fu C, Hao S, Liu Z, et al. SOD2 ameliorates pulmonary hypertension in a murine model of sleep apnea via suppressing expression of NLRP3 in CD11b+cells[J]. Respir Res, 2020, 21(1): 9.
|
7 |
Jia H, Liu Y, Guo D, et al. PM2.5-induced pulmonary inflammation via activating of the NLRP3/caspase-1 signaling pathway[J]. Environ Toxicol, 2021, 36(3): 298-307.
|
8 |
Puccini M, Landmesser U, Rauch U. Pleiotropic effects of PCSK9: focus on thrombosis and haemostasis[J]. Metabolites, 2022, 12(3): 226.
|
9 |
夏佳春,侯 磊. PCSK9在动脉粥样硬化性心血管疾病炎性反应中的作用[J]. 国际心血管病杂志,2023, 50(1): 5-8.
|
10 |
祝 青,郭 琪,吴 颖,等. 前蛋白转化酶枯草溶菌素9对革兰阴性菌脓毒症预后的评估价值[J]. 国际检验医学杂志,2021, 42(8): 907-911.
|
11 |
Frᶏtczak A, Polak K, Szczepanek M, et al. The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus[J]. Postepy Dermatol Alergol, 2022, 39(4): 645-650.
|
12 |
Ministrini S, Carbone F. PCSK9 and inflammation: Their role in autoimmune diseases, with a focus on rheumatoid arthritis and systemic lupus erythematosus[J]. Curr Med Chem, 2022, 29(6): 970-979.
|
13 |
Huang L, Wu H, Wu Y, et al. Pcsk9 knockout aggravated experimental apical periodontitis via LDLR[J]. J Dent Res, 2022, 101(1): 83-92.
|
14 |
Zhong D X, Zhang Y, Jin Q, et al. Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines[J]. Pulm Circ, 2021, 11(4): 20458940211051292.
|
15 |
Luna-López R, Ruiz Martín A, Escribano Subías P. Pulmonary arterial hypertension[J]. Med Clin (Barc), 2022, 158(12): 622-629.
|
16 |
Humbert Marc, Kovacs Gabor, Hoeper Marius M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38): 3618-3731.
|
17 |
任成山,卞士柱,胡明冬. 肺动脉高压的成因及治疗新理念[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(1): 1-5.
|
18 |
Zhong DX, Zhang Y, Jin Q, et al. Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines[J]. Pulm Circ, 2021, 11(4): 20458940211051292.
|
19 |
Xu WJ, Wu Q, He WN, et al. Interleukin-6 and pulmonary hypertension:from physiopathology to therapy[J]. Front Immunol, 2023, 14: 1181987.
|
20 |
Białecka M, Dziedziejko V, Safranow K, et al. Could tumor necrosis factor serve as a marker for cardiovascular risk factors and left ventricular hypertrophy in patients with early-onset coronary artery disease?[J]. Diagnostics, 2024, 14(4): 449.
|
21 |
Midtbø H, Kringeland E, Gerdts E, et al. Biomarkers of inflammation and left ventricular remodelling in psoriasis patients treated with infliximab[J]. Int J Immunopathol Pharmacol, 2022, 36: 03946320221111131.
|
22 |
Wang Q, Zheng B, Chen P, et al. Leptin and PCSK9 concentrations are associated with vascular endothelial cytokines in patients with stable coronary heart disease[J]. Open Med, 2022, 17(1): 185-190.
|
23 |
Wang Z, Chen X, Liu J, et al. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264. 7 macrophages via activating the PPARγ pathway[J]. Autoimmunity, 2022, 55(4): 223-232.
|
24 |
Elseweidy MM, Elswefy SE, Younis NN, et al. The modulation of PCSK-9 and GAGs by 10-dehydrogingerdione and pentoxifylline in hyperlipidemic rabbits[J]. Nat Prod Res, 2020, 34(16): 2372-2377.
|
25 |
Furuhashi M, Kataoka Y, Nishikawa R, et al. Circulating PCSK7 level is independently associated with obesity, triglycerides level and fatty liver index in a general population without medication[J]. J Atheroscler Thromb, 2022, 29(9): 1275-1284.
|
26 |
Petroglou D, Kanellos I, Savopoulos C, et al. The LDL-receptor and its molecular properties: from theory to novel biochemical and pharmacological approaches in reducing LDL-cholesterol[J]. Curr Med Chem, 2020, 27(2): 317-333.
|
27 |
Reljic D, Herrmann HJ, Neurath MF, et al. Iron beats electricity: Resistance training but not whole-body electromyostimulation improves cardiometabolic health in obese metabolic syndrome patients during caloric restriction-A randomized-controlled study[J]. Nutrients, 2021, 13(5): 1640.
|
28 |
Hu Y, Chi L, Kuebler WM, et al. Perivascular inflammation in pulmonary arterial hypertension[J]. Cells, 2020, 9(11): 2338.
|
29 |
Ortona S, Barisione C, Ferrari PF, et al. PCSK9 and other metabolic targets to counteract ischemia/reperfusion injury in acute myocardial infarction and visceral vascular surgery[J]. J Clin Med, 2022, 11(13): 3638.
|
30 |
刘志文,那日苏,马 聪. 血清PCSK9、vWF和apoM水平在2型糖尿病并发大血管病变中的诊断价值[J]. 检验医学与临床,2023, 20(4): 500-505.
|
31 |
Kheirkhah A, Lamina C, Rantner B, et al. Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: the CAVASIC study[J]. Atherosclerosis, 2021, 316: 41-47.
|
32 |
Ye P, Jiang XM, Qian WC, et al. Inhibition of PCSK9 improves the development of pulmonary arterial hypertension via down-regulating Notch3 expression[J]. Cardiovasc Drugs Ther, 2023, 31: 1-12.
|
33 |
Guo Y, Yan B, Gui Y, et al. Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall[J]. J Cell Physiol, 2021, 236(4): 2333-2351.
|